MIF and neoplasm: CD74 primarily promotes tumour progression through its signalling function, making it a potential tumour marker or targeted drug target [28] Due to the absence of targeted inhibitors for CD74, the MIF inhibitor ISO‐1 was chosen to inhibit CD74 function by occupying the binding domain of MIF.